Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (TA736)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 October 2021
Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (TA661)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 November 2020
Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal) (TA570)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 March 2019
Dinutuximab beta for treating neuroblastoma (TA538)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 August 2018
Cancer of the upper aerodigestive tract: assessment and management in people aged 16 and over (NG36)Product type:GuidanceProgramme:NICE guidelineLast updated: 6 June 2018Published: 10 February 2016
Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (TA473)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 31 August 2017
Minimally invasive video‑assisted parathyroidectomy (IPG501)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 23 August 2014
Minimally invasive video-assisted thyroidectomy (IPG499)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 23 August 2014
Transoral carbon dioxide laser surgery for primary treatment of oropharyngeal malignancy (IPG484)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 27 March 2014
Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck (TA145)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 June 2008
Interstitial photodynamic therapy for malignant parotid tumours (IPG259)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 23 April 2008
Thoracoscopic excision of mediastinal parathyroid tumours (IPG247)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 12 December 2007
Improving outcomes in head and neck cancers (CSG6)Product type:GuidanceProgramme:Cancer service guidelinePublished: 24 November 2004
Endoscopic transsphenoidal pituitary adenoma resection (IPG32)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 17 December 2003
Suspected cancer (QS124)Product type:Quality standardLast updated: 5 December 2017Published: 30 June 2016
Dusquetide for treating oral mucositis during chemoradiation for head and neck cancer [ID3830]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Atezolizumab for adjuvant treatment of high-risk locally advanced squamous cell head and neck cancer [ID4052]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck cancer [ID6199]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6406]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Leukocyte interleukin in combination for neoadjuvant treatment of resectable locally advanced squamous cell head and neck cancer [ID6390]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
High linear energy transfer radiation for carbon ion beam therapyStatus:Topic selectionProgramme:Interventional procedures guidanceExpected publication date: TBC
Pembrolizumab for neoadjuvant and with radiotherapy for adjuvant treatment of newly diagnosed resectable locally advanced squamous cell head and neck cancer [ID6477]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC